Skip to main content

Table 3 Effect of the compound 5-a treatment on the hematologic profile

From: The nephroprotective potential of selected synthetic compound against gentamicin induced nephrotoxicity

Groups

Neutrophils

(%)

Lymphocytes

(%)

WBC

(x103/μl)

RBC

(x106/μl)

Hb (g/dL)

Platelets

(x103/μl)

Normal Saline (0.15 μl/kg)

32.6 ± 0.50e

63 ± 0.70c

11.5 ± 0.18c

9.15 ± 0.005a

15.3 ± 0.03a

715.8 ± 1.24a

GM (100 mg/kg)

45.3 ± 0.64a

75.2 ± 0.86a

24.2 ± 0.25a

3.11 ± 0.008e

10.3 ± 0.07e

434.2 ± 1.15c

Dexa (10 mg/kg) + GM (100 mg/kg)

37.12 ± 0.62b

65.9 ± 1.01b

9.7 ± 0.12d

4.04 ± 0.005d

11.4 ± 0.04d

461 ± 0.70b

5-a (5 mg/kg) + GM (100 mg/kg)

34.9 ± 0.53c

61.2 ± 0.58c

11.7 ± 0.24c

8.07 ± 0.005c

14.5 ± 0.07b

694.8 ± 0.58a

5-a (10 mg/kg) + GM (100 mg/kg)

33.3 ± 0.50d

54 ± 0.70d

13.8 ± 0.11b

7.15 ± 0.015b

13.6 ± 0.05c

701.4 ± 0.92a

  1. Each value represents ± S.E.M (n = 5), analyzed by using One-way ANOVA (Analysis of variance) using the Duncan test for multiple comparisons. The values having different alphabetical superscriptions in the column significantly different (p ≤ 0.05)
  2. Whereas WBC White blood cell, RBC Red blood cell, Hb Hemoglobin, GM Gentamycin, Dexa dexamethasone, 5-a 2-{5-[(2-hydroxyethyl)-sulfanyl]-1,3,4-oxadiazol-2-yl} phenol